Gemcitabine, dexamethasone and cisplatin (GDP) is an effective and well-tolerated mobilization regimen for relapsed and refractory lymphoma: a single center experience

BACKGROUND/AIM: Gemcitabine, dexamethasone and cisplatin (GDP) is a well-established salvage regimen for relapsed and refractory lymphomas. In this study, we aimed to share our experience with the patients who received GDP/R-GDP (rituximab-gemcitabine, dexamethasone and cisplatin) for stem cell mobi...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Wydane w:Turk J Med Sci
Główni autorzy: BATGİ, Hikmettullah, BAŞCI1, Semih, DAL1, Mehmet Sinan, KIZIL ÇAKAR, Merih, UNCU ULU, Bahar, YİĞENOĞLU, Tuğçe Nur, ÖZCAN, Nurgül, KILINÇ, Ali, MERDİN, Alparslan, YILDIZ, Jale, BAKIRTAŞ, Mehmet, ŞAHİN, Derya, DARÇIN, Tahir, İSKENDER, Dicle, BAYSAL, Nuran Ahu, ALTUNTAŞ, Fevzi
Format: Artigo
Język:Inglês
Wydane: The Scientific and Technological Research Council of Turkey 2021
Hasła przedmiotowe:
Article
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8203130/
https://ncbi.nlm.nih.gov/pubmed/33237657
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3906/sag-2008-114
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy